{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T18:32:53Z","timestamp":1793298773217,"version":"4.5.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,7,19]],"date-time":"2019-07-19T00:00:00Z","timestamp":1563494400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31571202"],"award-info":[{"award-number":["31571202"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31271136"],"award-info":[{"award-number":["31271136"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005089","name":"Beijing Municipal Natural Science Foundation","doi-asserted-by":"publisher","award":["7192018"],"award-info":[{"award-number":["7192018"]}],"id":[{"id":"10.13039\/501100005089","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Importation and Development of High-Caliber Talents Project of Beijing Municipal Institutions","award":["CIT&TCD201504087"],"award-info":[{"award-number":["CIT&TCD201504087"]}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Nucleic Acids"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.omtn.2019.07.008","type":"journal-article","created":{"date-parts":[[2019,7,23]],"date-time":"2019-07-23T19:43:20Z","timestamp":1563911000000},"page":"726-740","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":139,"special_numbering":"C","title":["Exosomal DNA Aptamer Targeting \u03b1-Synuclein Aggregates Reduced Neuropathological Deficits in a Mouse Parkinson\u2019s Disease Model"],"prefix":"10.1016","volume":"17","author":[{"given":"Xiaoxi","family":"Ren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenqin","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haixia","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongchang","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianliang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 6","key":"10.1016\/j.omtn.2019.07.008_bib1","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1002\/mds.10557","article-title":"Neuropathological spectrum of synucleinopathies","volume":"18","author":"Jellinger","year":"2003","journal-title":"Mov. Disord."},{"key":"10.1016\/j.omtn.2019.07.008_bib2","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/mds.26332","article-title":"Basic science breaks through: New therapeutic advances in Parkinson\u2019s disease","volume":"30","author":"Brundin","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.omtn.2019.07.008_bib3","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/0896-6273(95)90302-X","article-title":"The precursor protein of non-A beta component of Alzheimer\u2019s disease amyloid is a presynaptic protein of the central nervous system","volume":"14","author":"Iwai","year":"1995","journal-title":"Neuron"},{"key":"10.1016\/j.omtn.2019.07.008_bib4","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/42166","article-title":"Alpha-synuclein in Lewy bodies","volume":"388","author":"Spillantini","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2019.07.008_bib5","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/mds.26481","article-title":"Development of Passive Immunotherapies for Synucleinopathies","volume":"31","author":"Bergstr\u00f6m","year":"2016","journal-title":"Mov. Disord."},{"key":"10.1016\/j.omtn.2019.07.008_bib6","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.jmb.2009.06.063","article-title":"Structural reorganization of alpha-synuclein at low pH observed by NMR and REMD simulations","volume":"391","author":"Wu","year":"2009","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.omtn.2019.07.008_bib7","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/mds.26428","article-title":"Combination therapies: The next logical Step for the treatment of synucleinopathies?","volume":"31","author":"Valera","year":"2016","journal-title":"Mov. Disord."},{"key":"10.1016\/j.omtn.2019.07.008_bib8","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s13311-015-0397-z","article-title":"Immunotherapeutic Approaches Targeting Amyloid-\u03b2, \u03b1-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders","volume":"13","author":"Valera","year":"2016","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.omtn.2019.07.008_bib9","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3109\/13506129.2011.582902","article-title":"The generic amyloid formation inhibition effect of a designed small aromatic \u03b2-breaking peptide","volume":"18","author":"Frydman-Marom","year":"2011","journal-title":"Amyloid"},{"key":"10.1016\/j.omtn.2019.07.008_bib10","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1007\/s12035-015-9173-7","article-title":"Treatment with Trehalose Prevents Behavioral and Neurochemical Deficits Produced in an AAV \u03b1-Synuclein Rat Model of Parkinson\u2019s Disease","volume":"53","author":"He","year":"2016","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.omtn.2019.07.008_bib11","doi-asserted-by":"crossref","first-page":"e241","DOI":"10.1038\/mtna.2015.14","article-title":"Normalization of Overexpressed \u03b1-Synuclein Causing Parkinson\u2019s Disease By a Moderate Gene Silencing With RNA Interference","volume":"4","author":"Takahashi","year":"2015","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2019.07.008_bib12","doi-asserted-by":"crossref","first-page":"13454","DOI":"10.1523\/JNEUROSCI.1292-12.2012","article-title":"Antibody-aided clearance of extracellular \u03b1-synuclein prevents cell-to-cell aggregate transmission","volume":"32","author":"Bae","year":"2012","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.omtn.2019.07.008_bib13","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.neuron.2005.05.010","article-title":"Effects of alpha-synuclein immunization in a mouse model of Parkinson\u2019s disease","volume":"46","author":"Masliah","year":"2005","journal-title":"Neuron"},{"key":"10.1016\/j.omtn.2019.07.008_bib14","doi-asserted-by":"crossref","first-page":"e19338","DOI":"10.1371\/journal.pone.0019338","article-title":"Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease","volume":"6","author":"Masliah","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.omtn.2019.07.008_bib15","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2019.07.008_bib16","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1111\/j.1471-4159.2011.07337.x","article-title":"Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain","volume":"118","author":"Boutajangout","year":"2011","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.omtn.2019.07.008_bib17","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.neuron.2013.07.046","article-title":"Anti-tau antibodies that block tau aggregate seeding in\u00a0vitro markedly decrease pathology and improve cognition in\u00a0vivo","volume":"80","author":"Yanamandra","year":"2013","journal-title":"Neuron"},{"key":"10.1016\/j.omtn.2019.07.008_bib18","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/j.1471-4159.2010.06683.x","article-title":"Intracerebroventricular infusion of monoclonal antibody or its derived Fab fragment against misfolded forms of SOD1 mutant delays mortality in a mouse model of ALS","volume":"113","author":"Gros-Louis","year":"2010","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.omtn.2019.07.008_bib19","doi-asserted-by":"crossref","first-page":"11563","DOI":"10.1073\/pnas.0505321102","article-title":"Suppression of Huntington\u2019s disease pathology in Drosophila by human single-chain Fv antibodies","volume":"102","author":"Wolfgang","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2019.07.008_bib20","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s00018-016-2345-4","article-title":"Aptamer and its applications in neurodegenerative diseases","volume":"74","author":"Qu","year":"2017","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.omtn.2019.07.008_bib21","doi-asserted-by":"crossref","first-page":"39697","DOI":"10.1074\/jbc.M305297200","article-title":"Characterization of 2\u2032-fluoro-RNA aptamers that bind preferentially to disease-associated conformations of prion protein and inhibit conversion","volume":"278","author":"Rhie","year":"2003","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.omtn.2019.07.008_bib22","doi-asserted-by":"crossref","first-page":"13102","DOI":"10.1074\/jbc.M310928200","article-title":"Structural determinants of conformationally selective, prion-binding aptamers","volume":"279","author":"Sayer","year":"2004","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.omtn.2019.07.008_bib23","doi-asserted-by":"crossref","first-page":"e668","DOI":"10.3390\/ijms19030668","article-title":"Aptamers Selected for Recognizing Amyloid \u03b2-Protein-A Case for Cautious Optimism","volume":"19","author":"Rahimi","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omtn.2019.07.008_bib24","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.omtn.2018.02.011","article-title":"Novel DNA Aptamers for Parkinson\u2019s Disease Treatment Inhibit \u03b1-Synuclein Aggregation and Facilitate its Degradation","volume":"11","author":"Zheng","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2019.07.008_bib25","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.tcb.2008.11.003","article-title":"Shedding microvesicles: artefacts no more","volume":"19","author":"Cocucci","year":"2009","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.omtn.2019.07.008_bib26","doi-asserted-by":"crossref","first-page":"4390","DOI":"10.1016\/j.biomaterials.2014.02.003","article-title":"Microvesicle-mediated delivery of transforming growth factor \u03b21 siRNA for the suppression of tumor growth in mice","volume":"35","author":"Zhang","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.omtn.2019.07.008_bib27","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.molcel.2010.06.010","article-title":"Secreted monocytic miR-150 enhances targeted endothelial cell migration","volume":"39","author":"Zhang","year":"2010","journal-title":"Mol. Cell"},{"key":"10.1016\/j.omtn.2019.07.008_bib28","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nbt.1830","article-title":"SiRNA delivery with exosome nanoparticles","volume":"29","author":"van den Boorn","year":"2011","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtn.2019.07.008_bib29","doi-asserted-by":"crossref","first-page":"5262","DOI":"10.1158\/1078-0432.CCR-07-1157","article-title":"Transforming growth factor-beta and the immune response: implications for anticancer therapy","volume":"13","author":"Wrzesinski","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omtn.2019.07.008_bib30","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nbt.1807","article-title":"Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes","volume":"29","author":"Alvarez-Erviti","year":"2011","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtn.2019.07.008_bib31","doi-asserted-by":"crossref","first-page":"17543","DOI":"10.1038\/srep17543","article-title":"Targeted exosome-mediated delivery of opioid receptor Mu siRNA for the treatment of morphine relapse","volume":"5","author":"Liu","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtn.2019.07.008_bib32","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1002\/mds.25978","article-title":"Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice","volume":"29","author":"Cooper","year":"2014","journal-title":"Mov. Disord."},{"key":"10.1016\/j.omtn.2019.07.008_bib33","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1126\/science.1227157","article-title":"Pathological \u03b1-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice","volume":"338","author":"Luk","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.omtn.2019.07.008_bib34","doi-asserted-by":"crossref","first-page":"E912","DOI":"10.1073\/pnas.1512876113","article-title":"Induction of de novo \u03b1-synuclein fibrillization in a neuronal model for Parkinson\u2019s disease","volume":"113","author":"Fares","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2019.07.008_bib35","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jsb.2004.08.002","article-title":"The binding of thioflavin-T to amyloid fibrils: localisation and implications","volume":"149","author":"Krebs","year":"2005","journal-title":"J.\u00a0Struct. Biol."},{"key":"10.1016\/j.omtn.2019.07.008_bib36","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.neuron.2011.08.033","article-title":"Exogenous \u03b1-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death","volume":"72","author":"Volpicelli-Daley","year":"2011","journal-title":"Neuron"},{"key":"10.1016\/j.omtn.2019.07.008_bib37","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1016\/j.celrep.2014.05.033","article-title":"\u0391-synuclein immunotherapy blocks uptake and templated propagation of misfolded \u03b1-synuclein and neurodegeneration","volume":"7","author":"Tran","year":"2014","journal-title":"Cell Rep."},{"key":"10.1016\/j.omtn.2019.07.008_bib38","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/ana.23659","article-title":"Neuropathologic substrates of Parkinson disease dementia","volume":"72","author":"Irwin","year":"2012","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.omtn.2019.07.008_bib39","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1084\/jem.20112457","article-title":"Intracerebral inoculation of pathological \u03b1-synuclein initiates a rapidly progressive neurodegenerative \u03b1-synucleinopathy in mice","volume":"209","author":"Luk","year":"2012","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.omtn.2019.07.008_bib40","first-page":"75","article-title":"A comprehensive overview of exosomes as drug delivery vehicles - endogenous nanocarriers for targeted cancer therapy","volume":"1846","author":"Johnsen","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.omtn.2019.07.008_bib41","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1016\/j.biomaterials.2013.11.083","article-title":"A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy","volume":"35","author":"Tian","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.omtn.2019.07.008_bib42","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nrneurol.2009.135","article-title":"Biological fluid biomarkers in neurodegenerative parkinsonism","volume":"5","author":"Eller","year":"2009","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.omtn.2019.07.008_bib43","doi-asserted-by":"crossref","first-page":"32046","DOI":"10.1074\/jbc.M201750200","article-title":"Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability","volume":"277","author":"Dahlgren","year":"2002","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.omtn.2019.07.008_bib44","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1006\/jsbi.2000.4264","article-title":"Amyloid fibril formation and seeding by wild-type human lysozyme and its disease-related mutational variants","volume":"130","author":"Morozova-Roche","year":"2000","journal-title":"J.\u00a0Struct. Biol."},{"key":"10.1016\/j.omtn.2019.07.008_bib45","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1016\/j.neurobiolaging.2011.09.027","article-title":"GSPE interferes with tau aggregation in\u00a0vivo: implication for treating tauopathy","volume":"33","author":"Santa-Maria","year":"2012","journal-title":"Neurobiol. Aging"}],"container-title":["Molecular Therapy - Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253119301982?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253119301982?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T11:38:28Z","timestamp":1717673908000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253119301982"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":45,"alternative-id":["S2162253119301982"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2019.07.008","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exosomal DNA Aptamer Targeting \u03b1-Synuclein Aggregates Reduced Neuropathological Deficits in a Mouse Parkinson\u2019s Disease Model","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2019.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Author(s).","name":"copyright","label":"Copyright"}]}}